We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...

Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue ...

CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal franchise contrasting with strong growth in other areas. U.S. net sales of EYLEA were $736 million ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories,” President and CEO Leonard Schleifer said in a statement.

“Increasing our footprint in the US is important,” said Regeneron Chief Executive Officer Leonard Schleifer said in an interview. “Demand for our products is growing rather fast,” he said.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...